Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 397

The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.

International Expert Consensus on Switching Platelet P2Y 12 Receptor–Inhibiting Therapies

Open access
Angiolillo, Dominick J., Rollini, Fabiana, Storey, Robert F., Bhatt, Deepak L., James, Stefan, Schneider, David J., Sibbing, Dirk, So, Derek Y.F., Trenk, Dietmar, Alexopoulos, Dimitrios, Gurbel, Paul A., Hochholzer, Willibald, De Luca, Leonardo, Bonello, Laurent, Aradi, Daniel, Cuisset, Thomas, Tantry, Udaya S., Wang, Tracy Y., Valgimigli, Marco, Waksman, Ron, Mehran, Roxana, Montalescot, Gilles, Franchi, Francesco, Price, Matthew J.·2017·Circulation

Abstract

Dual antiplatelet therapy with aspirin and a P2Y 12 inhibitor is the treatment of choice for the prevention of atherothrombotic events in patients with acute coronary syndromes and for those undergoing percutaneous coronary interventions. The availability of different oral P2Y 12 inhibitors (clopidogrel, prasugrel, ticagrelor) has enabled physicians to contemplate switching among therapies because of specific clinical scenarios. The recent introduction of an intravenous P2Y 12 inhibitor (cangrelor) further adds to the multitude of modalities and settings in which switching therapies may occur. In clinical practice, it is not uncommon to switch P2Y 12 inhibitor, and switching may be attributed to a variety of factors. However, concerns about the safety of switching between these agents have emerged. Practice guidelines have not fully elaborated on how to switch therapies, leaving clinicians with limited guidance on when and how to switch therapies when needed. This prompted the development of this expert consensus document by key leaders from North America and Europe with expertise in basic, translational, and clinical sciences in the field of antiplatelet therapy. This expert consensus provides an overview of the pharmacology of P2Y 12 inhibitors, different modalities and definitions of switching, and available literature and recommendations for switching between P2Y 12 inhibitors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.117.031164

Cites

85 of 85 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 85 references

Cited by

See all 397

Metadata

Authors
Angiolillo, D. J., Rollini, F., Storey, R. F., Bhatt, D. L., James, S., Schneider, D. J., Sibbing, D., So, D. Y. F., Trenk, D., Alexopoulos, D., Gurbel, P. A., Hochholzer, W., De Luca, L., Bonello, L., Aradi, D., Cuisset, T., Tantry, U. S., Wang, T. Y., Valgimigli, M., Waksman, R., Mehran, R., Montalescot, G., Franchi, F., & Price, M. J.
Venue
Circulation
Published
2017-11-14
Volume
136
Issue
20
Pages
1955-1975
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2766257307
Cited by
397
References
85
FWCI
30.99
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: International Expert Consensus on Switching Platelet P2Y 12 Receptor–Inhibiting Therapies. https://app.cochat.ai/papers/10.1161/circulationaha.117.031164
The paper
Angiolillo, D. J., Rollini, F., Storey, R. F., Bhatt, D. L., James, S., Schneider, D. J., Sibbing, D., So, D. Y. F., Trenk, D., Alexopoulos, D., Gurbel, P. A., Hochholzer, W., De Luca, L., Bonello, L., Aradi, D., Cuisset, T., Tantry, U. S., Wang, T. Y., Valgimigli, M., . . . Price, M. J. (2017). International Expert Consensus on Switching Platelet P2Y 12 Receptor–Inhibiting Therapies. Circulation. https://doi.org/10.1161/circulationaha.117.031164

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.